LV5233A3 - (s)-alpha-etil-2-okso-1-pirolidinacetamida l-enantiomers ar antihipoksisku un antiisemisku aktivitati - Google Patents

(s)-alpha-etil-2-okso-1-pirolidinacetamida l-enantiomers ar antihipoksisku un antiisemisku aktivitati

Info

Publication number
LV5233A3
LV5233A3 LV930379A LV930379A LV5233A3 LV 5233 A3 LV5233 A3 LV 5233A3 LV 930379 A LV930379 A LV 930379A LV 930379 A LV930379 A LV 930379A LV 5233 A3 LV5233 A3 LV 5233A3
Authority
LV
Latvia
Prior art keywords
radical
oxo
alpha
ethyl
pyrrolidineacetamide
Prior art date
Application number
LV930379A
Other languages
English (en)
Inventor
Jean Gobert
Jean-Pierre Geerts
Guy Bodson
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10560974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV5233(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of LV5233A3 publication Critical patent/LV5233A3/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Seasonings (AREA)
  • Cosmetics (AREA)
LV930379A 1984-05-15 1993-05-19 (s)-alpha-etil-2-okso-1-pirolidinacetamida l-enantiomers ar antihipoksisku un antiisemisku aktivitati LV5233A3 (lv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848412357A GB8412357D0 (en) 1984-05-15 1984-05-15 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
LV5233A3 true LV5233A3 (lv) 1993-10-10

Family

ID=10560974

Family Applications (1)

Application Number Title Priority Date Filing Date
LV930379A LV5233A3 (lv) 1984-05-15 1993-05-19 (s)-alpha-etil-2-okso-1-pirolidinacetamida l-enantiomers ar antihipoksisku un antiisemisku aktivitati

Country Status (33)

Country Link
US (3) US4696943A (lv)
EP (1) EP0162036B1 (lv)
JP (1) JPH0629186B2 (lv)
KR (1) KR920003819B1 (lv)
CN (1) CN1015541B (lv)
AT (1) ATE45567T1 (lv)
AU (1) AU574465B2 (lv)
BG (2) BG50156A3 (lv)
CA (1) CA1235129A (lv)
CY (2) CY1567A (lv)
DE (3) DE10075021I1 (lv)
DK (1) DK163501C (lv)
ES (2) ES8608485A1 (lv)
FI (1) FI80673C (lv)
GB (1) GB8412357D0 (lv)
GE (1) GEP20002001B (lv)
GR (1) GR851155B (lv)
HK (1) HK52391A (lv)
IE (1) IE59950B1 (lv)
IL (1) IL75179A (lv)
LT (1) LT2584B (lv)
LU (2) LU90615I2 (lv)
LV (1) LV5233A3 (lv)
MY (2) MY101726A (lv)
NL (1) NL300028I2 (lv)
NO (2) NO164534C (lv)
PL (2) PL144346B1 (lv)
PT (1) PT80460B (lv)
SA (1) SA01210656A (lv)
SG (1) SG80090G (lv)
SU (3) SU1402260A3 (lv)
UA (1) UA6158A1 (lv)
ZA (1) ZA853635B (lv)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827389D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US6124473A (en) * 1998-05-08 2000-09-26 Ucb, S.A. Process for preparing (s)- and (R)-α-ethyl-2-oxo-1-pyrrolidineacetamide
US6107492A (en) * 1998-05-08 2000-08-22 Ucb, S.A. Process for the preparation of levetiracetam
EA002379B1 (ru) * 1999-07-21 2002-04-25 Российский Государственный Педагогический Университет Им. А.И.Герцена Средство, обладающее антиишемической, гипотензивной и антигипоксической активностью
EA002380B1 (ru) * 1999-07-21 2002-04-25 Российский Государственный Педагогический Университет Им. А.И.Герцена Антиишемическое средство
HUP0204023A3 (en) * 1999-12-01 2005-03-29 Ucb Sa A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders and pharmaceutical compositions containing them
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) * 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
AU2002224847A1 (en) * 2000-11-21 2002-06-03 U C B, S.A. N-alkylated gaba compounds, processes for their preparation and their use as medicaments
MXPA03005889A (es) 2000-12-28 2005-02-14 Daiichi Seiyaku Co Agente para tratamiento terapeutico y profilactico del dolor neuropatico.
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
IL160045A0 (en) 2001-08-10 2004-06-20 Ucb Sa Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
US20040242671A1 (en) * 2001-10-08 2004-12-02 Renee Grimee Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
WO2003094913A1 (en) * 2002-05-14 2003-11-20 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
CN1802352A (zh) * 2003-02-03 2006-07-12 特瓦制药工业有限公司 制备左乙拉西坦的方法
ES2214147B1 (es) 2003-02-28 2005-10-01 Farma-Lepori S.A. Procedimiento de obtencion de un agente antiepileptico.
AU2003217438A1 (en) * 2003-03-18 2004-10-11 Hetero Drugs Limited Novel crystalline forms of levetiracetam
EP1663968A1 (en) * 2003-09-05 2006-06-07 Ranbaxy Laboratories Limited Process for the preparation of pure levetiracetam
ES2390455T3 (es) * 2003-09-24 2012-11-13 Ucb Pharma, S.A. Procedimiento para la preparación de derivados de 2-oxo-1-pirrolidina
EP1706376B1 (en) 2003-12-02 2009-03-04 UCB Pharma, S.A. Imidazole derivatives, processes for preparing them and their uses
US7531673B2 (en) 2004-02-18 2009-05-12 Dr. Reddy's Laboratories Limited Preparation of amino acid amides
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
ZA200707250B (en) * 2005-01-27 2009-06-24 Alembic Ltd Extended release formulation of levetiracetam
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006090265A2 (en) * 2005-02-28 2006-08-31 Ranbaxy Laboratories Limited Processes for the preparation of levetiracetam, its intermediate and the use of levetiracetam in pharmaceutical compositions
EP1863761A1 (en) * 2005-03-10 2007-12-12 Rubamin Limited Process for preparing levetiracetam
US8216611B2 (en) 2005-03-30 2012-07-10 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
US20080194840A1 (en) * 2005-04-01 2008-08-14 Rubamin Laboratories Limited Process for Preparing Levetiracetam and Racemization of (R)- and (S)-2-Amino Butynamide and the Corresponding Acid Derivatives
EP1912966A2 (en) 2005-06-01 2008-04-23 Ucb, S.A. 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
CA2581831C (en) 2005-07-26 2013-11-12 Ucb Pharma, S.A. Pharmaceutical compositions comprising levetiracetam and process for their preparation
US8338621B2 (en) 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
JP2009524658A (ja) * 2006-01-24 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド レベチラセタム製剤、及びそれらの製造方法
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
CA2657571A1 (en) * 2006-07-25 2008-01-31 Zach System S.P.A. Process for the preparation of levetiracetam
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
CN101130504B (zh) * 2006-08-25 2010-07-28 苏州雅本化学股份有限公司 经合成、拆分与消旋化制备手性药物左乙拉西坦中间体(s)-(+)-2-氨基丁酰胺盐酸盐的方法
EP1932922A1 (de) * 2006-12-13 2008-06-18 Desitin Arzneimittel GmbH Schnelltest zum Nachweis von DNA-Sequenzen
WO2008077035A2 (en) * 2006-12-18 2008-06-26 Dr. Reddy's Laboratories Ltd. Processes for the preparation of levetiracetam
CN101333180B (zh) * 2007-06-29 2011-05-18 浙江华海药业股份有限公司 一种制备左乙拉西坦中间体的方法
US20090082422A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levetiracetam
WO2009050735A1 (en) * 2007-10-15 2009-04-23 Lupin Limited A novel polymorph of levetiracetam and a process for its preparation
US20090263481A1 (en) * 2008-04-17 2009-10-22 Atul Vishvanath Patil Levetiracetam formulations
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
EP2147911A1 (en) 2008-07-24 2010-01-27 ZaCh System S.p.A. Process for the preparation of levetiracetam
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
CN107243007A (zh) * 2008-10-16 2017-10-13 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
EP2179725A1 (en) 2008-10-23 2010-04-28 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising levetiracetam
EP2341777B1 (en) * 2008-11-07 2015-01-21 NovaBay Pharmaceuticals, Inc. Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
WO2010132693A2 (en) 2009-05-13 2010-11-18 Nektar Therapeutics Oligomer-containing pyrrolidine compounds
CN101885696A (zh) * 2009-05-14 2010-11-17 上海华理生物医药有限公司 一种合成高纯度左乙拉西坦的方法
US20120171125A1 (en) 2009-08-07 2012-07-05 Ucb Pharma, S.A. Methods for Enhancing the Cognitive Function
EP2298290A1 (en) 2009-09-16 2011-03-23 LEK Pharmaceuticals d.d. Controlled release composition comprising levetiracetam
US7939676B2 (en) * 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
CN102574869A (zh) 2009-10-23 2012-07-11 Ucb医药有限公司 2-氧代-1-吡咯烷基咪唑并噻二唑衍生物
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
US9187774B2 (en) 2010-02-26 2015-11-17 The Regents Of The University Of California Compositions and methods for the production of L-homoalanine
WO2011136751A2 (en) 2010-04-26 2011-11-03 Mahmut Bilgic Water soluble pharmaceutical composition
US9333175B2 (en) 2010-06-16 2016-05-10 Mylan Inc. Controlled release levetiracetam formulations and methods for producing the same
EP2492354A1 (en) 2011-02-23 2012-08-29 Institut National De La Recherche Agronomique (INRA) Method for identifying compounds useful in the treatment of photosensitive reflex epilepsy
RS54487B1 (en) 2011-04-18 2016-06-30 Ucb Biopharma Sprl 2-OXO-1-IMIDAZOLIDINIL DERIVATIVES IMIDAZOTIADIAZOL
EP2524910A1 (en) 2011-05-17 2012-11-21 DSM IP Assets B.V. Process for the resolution of aminobutyramide
CN102382027B (zh) * 2011-09-20 2013-11-13 浙江江北药业有限公司 一种左乙拉西坦的制备方法
CN102617436B (zh) * 2012-03-20 2014-02-12 浙江洪波化工有限公司 2-(2-氧代吡咯烷基）丁酰胺的制备方法
CN102633675A (zh) * 2012-04-10 2012-08-15 南京大学 一种dl-2-氨基丁酰胺制备方法
CN102675181B (zh) * 2012-06-07 2013-11-20 北京师宏药物研制中心 一种左乙拉西坦的制备方法
CN102702063B (zh) * 2012-06-15 2013-09-04 孙威 一种左乙拉西坦制备方法
WO2014012563A1 (en) 2012-07-20 2014-01-23 Ucb Pharma, S.A. Compounds for enhancing the cognitive function
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103012190B (zh) * 2012-12-05 2015-03-18 江苏拜克新材料有限公司 一种s-2-氨基丁酰胺盐酸盐的合成方法
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2908292T3 (es) 2013-03-15 2022-04-28 Aprecia Pharmaceuticals LLC Método de impresión tridimensional
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
MX2016009471A (es) 2014-01-21 2016-10-13 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso.
CN103922988A (zh) * 2014-04-29 2014-07-16 苏州天马精细化学品股份有限公司 一种左乙拉西坦粗品的纯化方法
CN103910649A (zh) * 2014-04-29 2014-07-09 苏州天马精细化学品股份有限公司 一种左乙拉西坦中间体（s）-n-[1-(氨基羰基)丙基]-4-氯代丁酰胺的合成方法
CN104860863B (zh) * 2015-04-10 2017-06-20 惠州信立泰药业有限公司 左乙拉西坦和含其的药物组合物
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
CN106432032B (zh) * 2016-09-14 2019-07-12 苏州天马药业有限公司 一种左乙拉西坦的制备方法
CN106591179B (zh) * 2016-12-05 2018-07-03 长兴制药股份有限公司 甲基包囊菌及其在选择性拆分制备(S)-α-乙基-2-氧-1-吡咯烷乙酸盐上的应用
HRP20220463T1 (hr) 2016-12-16 2022-05-27 Idorsia Pharmaceuticals Ltd Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa
CN108503610B (zh) 2017-02-24 2019-09-13 北京艾百诺医药股份有限公司 一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN107337628B (zh) * 2017-08-10 2022-02-08 浙江华海药业股份有限公司 一种制备左乙拉西坦的方法
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
CN110003074A (zh) 2019-04-23 2019-07-12 浙江华海药业股份有限公司 一种左乙拉西坦中间体的制备方法
TW202114655A (zh) 2019-08-14 2021-04-16 瑞士商辛鐵堤卡公司 左乙拉西坦(levetiracetam)之鞘內投藥
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
KR20230167032A (ko) 2021-02-26 2023-12-07 신데시 테라퓨틱스 에스아 인지 장애의 치료를 위한 화합물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB1583871A (en) * 1976-10-19 1981-02-04 Ucb Sa Anti-aggregants
FR2418790A1 (fr) * 1978-03-02 1979-09-28 Philagro Sa Nouveaux derives de pyrrolidinone-2 et compositions herbicides les contenant
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition

Also Published As

Publication number Publication date
SU1428195A3 (ru) 1988-09-30
CN1015541B (zh) 1992-02-19
CN85105301A (zh) 1987-01-14
KR920003819B1 (ko) 1992-05-15
IE851193L (en) 1985-11-15
GEP20002001B (en) 2000-03-10
DK163501C (da) 1992-07-27
HK52391A (en) 1991-07-19
SU1430392A1 (ru) 1988-10-15
DK212985D0 (da) 1985-05-14
EP0162036A1 (fr) 1985-11-21
CA1235129A (en) 1988-04-12
SA01210656A (ar) 2005-12-03
DE10199005I1 (de) 2001-07-12
LU90682I2 (fr) 2001-01-30
UA6158A1 (uk) 1994-12-29
ES8704893A1 (es) 1987-04-16
NO2001008I2 (no) 2005-05-30
SU1402260A3 (ru) 1988-06-07
CY2004007I1 (el) 2009-11-04
PL147386B1 (en) 1989-05-31
ES543124A0 (es) 1986-06-16
ES8704893B9 (es) 2012-02-07
JPH0629186B2 (ja) 1994-04-20
US4696943A (en) 1987-09-29
BG50156A3 (en) 1992-05-15
NO851933L (no) 1985-11-18
MY101725A (en) 1992-01-17
ZA853635B (en) 1985-12-24
GB8412357D0 (en) 1984-06-20
LU90615I2 (fr) 2000-10-02
US4943639A (en) 1990-07-24
DK163501B (da) 1992-03-09
ATE45567T1 (de) 1989-09-15
ES8608485A1 (es) 1986-06-16
NL300028I1 (nl) 2001-02-01
SG80090G (en) 1990-11-23
PT80460A (fr) 1985-06-01
EP0162036B1 (fr) 1989-08-16
AU574465B2 (en) 1988-07-07
DE10199005I2 (de) 2002-03-14
FI80673C (fi) 1990-07-10
IL75179A0 (en) 1985-09-29
LT2584B (lt) 1994-03-25
IE59950B1 (en) 1994-05-04
NO164534C (no) 1990-10-17
CY1567A (en) 1991-12-20
DK212985A (da) 1985-11-16
PL257385A1 (en) 1986-10-07
GR851155B (lv) 1985-11-25
AU4253085A (en) 1986-11-20
FI851875L (fi) 1985-11-16
PL144346B1 (en) 1988-05-31
MY101726A (en) 1992-01-17
CY2004007I2 (el) 2009-11-04
NL300028I2 (nl) 2001-06-01
US4837223A (en) 1989-06-06
BG47497A3 (en) 1990-07-16
NO164534B (no) 1990-07-09
IL75179A (en) 1988-05-31
KR850008336A (ko) 1985-12-16
JPS60252461A (ja) 1985-12-13
FI851875A0 (fi) 1985-05-13
FI80673B (fi) 1990-03-30
PT80460B (pt) 1987-08-19
PL253374A1 (en) 1986-05-06
DE10075021I1 (de) 2000-10-19
DE3572348D1 (de) 1989-09-21

Similar Documents

Publication Publication Date Title
LV5233A3 (lv) (s)-alpha-etil-2-okso-1-pirolidinacetamida l-enantiomers ar antihipoksisku un antiisemisku aktivitati
DE3572168D1 (de) (r)-alpha-ethyl-2-oxo-1-pyrrolidinacetamide